Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Army
US Department of Justice
Daiichi Sankyo

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,559,330

« Back to Dashboard

Summary for Patent: 4,559,330

Title: Use of 3,3'-azo-bis-(6-hydroxy benzoic acid) as a drug and pharmaceutical compositions containing the same
Abstract:A method of treating inflammatory diseases such as ulcerous colitis, comprising administration of 3,3'-azo-bis-(6-hydroxy benzoic acid) of the formula: ##STR1## or pharmaceutically acceptable salts thereof. Pharmaceutical compositions, especially for oral administration, contain said compound, or pharmaceutically acceptable salts thereof, together with pharmaceutically acceptable carriers and/or adjuvants.
Inventor(s): Agback; Karl H. (Uppsala, SE), Natvig; Tore (Uppsala, SE), Truelove; Sidney C. (Kirtlington, GB2)
Assignee: Pharmacia AB (Uppsala, SE)
Application Number:06/247,252
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,559,330

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden8002322Mar 26, 1980

International Patent Family for Patent: 4,559,330

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia549237► Subscribe
Australia6862481► Subscribe
Canada1179602► Subscribe
Germany3161216► Subscribe
European Patent Office0036637► Subscribe
Israel62382► Subscribe
JapanH0148247► Subscribe
JapanS56154417► Subscribe
Netherlands930101► Subscribe
Sweden8002322► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus